Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
Martin J. van den Bent(Erasmus MC Cancer Institute), AH Jacobs(University of Münster), David Schiff(University of Virginia), Marc C. Chamberlain(Center for Neuro-Oncology), Larry Junck(University of Michigan), Terri S. Armstrong(The University of Texas MD Anderson Cancer Center), M. J. B. Taphoorn(GGD Haaglanden), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Adam Waldman(Royal Society of Edinburgh), SM Chang(University of California, San Francisco), BG Baumert(Maastricht University Medical Centre), PY Wen(Brigham and Women's Hospital), DR Macdonald(Western University), DA Reardon(Duke Medical Center), JS Wefel(The University of Texas MD Anderson Cancer Center), Ali Choucair(Norton Healthcare), MA Vogelbaum(Cleveland Clinic), Kurt A. Jaeckle(Jacksonville College)
Cited by 649
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k